A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous CSL730 in Healthy Caucasian and Japanese Subjects
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs M-230 (Primary)
- Indications Autoimmune disorders; Epidermolysis bullosa; Idiopathic thrombocytopenic purpura
- Focus Adverse reactions
- Sponsors CSL Behring
- 08 Oct 2019 Planned End Date changed from 22 Sep 2019 to 1 May 2020.
- 08 Oct 2019 Planned primary completion date changed from 22 Sep 2019 to 1 May 2020.
- 02 Aug 2019 Status changed from recruiting to active, no longer recruiting.